Tarsus Pharmaceuticals Inc. Insider Trading

TARS

Last 12 months

Insiders sold $20M and bought nothing on the open market.

64% of the selling was scheduled in advance under 10b5-1 plans. President/CEO and Board Chair Bobak R. Azamian sold $2.36M on Mar 19 outside a plan. The last open-market buy by an executive or director was in Dec 2023.

Net open-market

−$20M

0 buys · 25 sales

Under a 10b5-1 plan

64%

of the value sold

Insiders who bought / sold

0 / 9

executives and directors

Last open-market buy

Dec 2023

Dec 15, 2023

Get an email when TARS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 15	William J Phd Link Director	Sold10b5-1 plan 3 parts	12,500	$78.38 average	980K	12%	Form 4
Sep 4	Elizabeth Yeu Lin Chief Medical Officer	Sold10b5-1 plan 4 parts	13,953	$87.50 average	$1.22M	46%	Form 4
Sep 4	Bobak R. Azamian President/CEO and Board Chair	Sold10b5-1 plan 2 parts	10,000	$90.56 average	906K	1.1%	Form 4
Sep 4	Seshadri Neervannan Chief Operating Officer	Sold10b5-1 plan	4,564	$85.00	388K	5.5%	Form 4
Sep 1 – 2	Elizabeth Yeu Lin Chief Medical Officer	Sold10b5-1 plan 3 parts	11,578	$77.56 average	898K	28%	Form 4
Sep 2	Bobak R. Azamian President/CEO and Board Chair	Sold10b5-1 plan	10,000	$80.06	801K	1.1%	Form 4
Jun 17	Bobak R. Azamian President/CEO and Board Chair	Sold10b5-1 plan 2 parts	10,000	$61.55 average	615K	1.1%	Form 4
Jun 16	Jeffrey S Farrow See Remarks	SoldNo plan	14,396	$60.95	877K	20%	Form 4
Jun 15	Katherine Goodrich Director	Sold10b5-1 plan	2,954	$62.08	183K	57%	Form 4
Jun 15	William J Phd Link Director	Sold10b5-1 plan 2 parts	12,500	$62.12 average	776K	10%	Form 4
Mar 20	Seshadri Neervannan Chief Operating Officer	Sold10b5-1 plan	2,989	$66.75	200K	3.5%	Form 4
Mar 17 – 19	Elizabeth Yeu Lin Chief Medical Officer	SoldNo plan 3 parts	1,144	$68.36 average	78K	2.7%	Form 4
Mar 17 – 19	Bryan Wahl General Counsel	SoldNo plan 3 parts	12,440	$68.36 average	850K	16%	Form 4
Mar 17 – 19	Dianne C. Whitfield Chief Human Resources Officer	SoldNo plan 3 parts	12,274	$68.36 average	839K	26%	Form 4
Mar 17 – 19	Bobak R. Azamian President/CEO and Board Chair	SoldNo plan 3 parts	34,603	$68.34 average	$2.36M	3.7%	Form 4
Mar 17 – 19	Seshadri Neervannan Chief Operating Officer	SoldNo plan 3 parts	11,324	$68.21 average	772K	12%	Form 4
Mar 17 – 19	Aziz Mottiwala Chief Commercial Officer	SoldNo plan 3 parts	13,056	$68.36 average	893K	18%	Form 4
Mar 17 – 19	Jeffrey S Farrow See Remarks	SoldNo plan 3 parts	6,430	$68.36 average	440K	13%	Form 4
Mar 16	William J Phd Link Director	Sold10b5-1 plan 3 parts	12,500	$68.79 average	860K	9.7%	Form 4
Mar 4	Seshadri Neervannan Chief Operating Officer	Sold10b5-1 plan	8,366	$76.67	641K	11%	Form 4
Jan 2	Dianne C. Whitfield Chief Human Resources Officer	Sold10b5-1 plan 4 parts	15,565	$80.67 average	$1.26M	40%	Form 4
Dec 24, 2025	Bobak R. Azamian President/CEO and Board Chair	Sold10b5-1 plan 2 parts	6,000	$82.51 average	495K	0.7%	Form 4
Dec 16, 2025	Dianne C. Whitfield Chief Human Resources Officer	Sold10b5-1 plan	7,397	$80.10	592K	16%	Form 4
Dec 16, 2025	Elizabeth Yeu Lin Chief Medical Officer	SoldNo plan	2,078	$79.50	165K	4.9%	Form 4
Dec 15, 2025	William J Phd Link Director	Sold10b5-1 plan 5 parts	22,946	$81.26 average	$1.86M	15%	Form 4
Sep 24, 2025	Bobak R. Azamian President/CEO and Board Chair	Sold10b5-1 plan	6,000	$55.37	332K	0.7%	Form 4
Sep 8, 2025	William J Phd Link Director	SoldNo plan	27,116	$57.00	$1.55M	15%	Form 4
Aug 11, 2025	Bobak R. Azamian President/CEO and Board Chair	Sold10b5-1 plan	6,000	$50.00	300K	0.7%	Form 4
Jun 17, 2025	Jeffrey S Farrow See Remarks	SoldNo plan	13,608	$40.42	550K	27%	Form 4
Jun 16, 2025	Elizabeth Yeu Lin Chief Medical Officer	SoldNo plan	1,006	$41.08	41K	2.7%	Form 4
Jun 9, 2025	Aziz Mottiwala Chief Commercial Officer	Sold10b5-1 plan	17,500	$43.76	766K	27%	Form 4
Mar 24, 2025	Bobak R. Azamian President/CEO and Board Chair	Sold10b5-1 plan	6,000	$50.00	300K	0.7%	Form 4
Mar 18, 2025 – Mar 20, 2025	Aziz Mottiwala Chief Commercial Officer	SoldNo plan 3 parts	10,565	$47.88 average	506K	14%	Form 4
Mar 18, 2025 – Mar 20, 2025	Seshadri Neervannan Chief Operating Officer	SoldNo plan 3 parts	7,583	$47.89 average	363K	8.7%	Form 4
Mar 18, 2025 – Mar 20, 2025	Bryan Wahl General Counsel	SoldNo plan 3 parts	9,686	$47.88 average	464K	16%	Form 4
Mar 18, 2025 – Mar 20, 2025	Dianne C. Whitfield Chief Human Resources Officer	SoldNo plan 3 parts	6,711	$47.88 average	321K	13%	Form 4
Mar 18, 2025 – Mar 20, 2025	Bobak R. Azamian President/CEO and Board Chair	SoldNo plan 3 parts	24,216	$48.03 average	$1.16M	2.7%	Form 4
Mar 18, 2025 – Mar 20, 2025	Jeffrey S Farrow See Remarks	SoldNo plan 3 parts	3,724	$47.88 average	178K	14%	Form 4

Sep 1510b5-1 plan
William J Phd Link
Director · sold 12,500 at avg $78.38
980K
12% of stake
Sep 410b5-1 plan
Elizabeth Yeu Lin
Chief Medical Officer · sold 13,953 at avg $87.50
$1.22M
46% of stake
Sep 410b5-1 plan
Bobak R. Azamian
President/CEO and Board Chair · sold 10,000 at avg $90.56
906K
1.1% of stake
Sep 410b5-1 plan
Seshadri Neervannan
Chief Operating Officer · sold 4,564 at $85.00
388K
5.5% of stake
Sep 1 – 210b5-1 plan
Elizabeth Yeu Lin
Chief Medical Officer · sold 11,578 at avg $77.56
898K
28% of stake
Sep 210b5-1 plan
Bobak R. Azamian
President/CEO and Board Chair · sold 10,000 at $80.06
801K
1.1% of stake
Jun 1710b5-1 plan
Bobak R. Azamian
President/CEO and Board Chair · sold 10,000 at avg $61.55
615K
1.1% of stake
Jun 16No plan
Jeffrey S Farrow
See Remarks · sold 14,396 at $60.95
877K
20% of stake
Jun 1510b5-1 plan
Katherine Goodrich
Director · sold 2,954 at $62.08
183K
57% of stake
Jun 1510b5-1 plan
William J Phd Link
Director · sold 12,500 at avg $62.12
776K
10% of stake
Mar 2010b5-1 plan
Seshadri Neervannan
Chief Operating Officer · sold 2,989 at $66.75
200K
3.5% of stake
Mar 17 – 19No plan
Elizabeth Yeu Lin
Chief Medical Officer · sold 1,144 at avg $68.36
78K
2.7% of stake
Mar 17 – 19No plan
Bryan Wahl
General Counsel · sold 12,440 at avg $68.36
850K
16% of stake
Mar 17 – 19No plan
Dianne C. Whitfield
Chief Human Resources Officer · sold 12,274 at avg $68.36
839K
26% of stake
Mar 17 – 19No plan
Bobak R. Azamian
President/CEO and Board Chair · sold 34,603 at avg $68.34
$2.36M
3.7% of stake
Mar 17 – 19No plan
Seshadri Neervannan
Chief Operating Officer · sold 11,324 at avg $68.21
772K
12% of stake
Mar 17 – 19No plan
Aziz Mottiwala
Chief Commercial Officer · sold 13,056 at avg $68.36
893K
18% of stake
Mar 17 – 19No plan
Jeffrey S Farrow
See Remarks · sold 6,430 at avg $68.36
440K
13% of stake
Mar 1610b5-1 plan
William J Phd Link
Director · sold 12,500 at avg $68.79
860K
9.7% of stake
Mar 410b5-1 plan
Seshadri Neervannan
Chief Operating Officer · sold 8,366 at $76.67
641K
11% of stake
Jan 210b5-1 plan
Dianne C. Whitfield
Chief Human Resources Officer · sold 15,565 at avg $80.67
$1.26M
40% of stake
Dec 24, 202510b5-1 plan
Bobak R. Azamian
President/CEO and Board Chair · sold 6,000 at avg $82.51
495K
0.7% of stake
Dec 16, 202510b5-1 plan
Dianne C. Whitfield
Chief Human Resources Officer · sold 7,397 at $80.10
592K
16% of stake
Dec 16, 2025No plan
Elizabeth Yeu Lin
Chief Medical Officer · sold 2,078 at $79.50
165K
4.9% of stake
Dec 15, 202510b5-1 plan
William J Phd Link
Director · sold 22,946 at avg $81.26
$1.86M
15% of stake
Sep 24, 202510b5-1 plan
Bobak R. Azamian
President/CEO and Board Chair · sold 6,000 at $55.37
332K
0.7% of stake
Sep 8, 2025No plan
William J Phd Link
Director · sold 27,116 at $57.00
$1.55M
15% of stake
Aug 11, 202510b5-1 plan
Bobak R. Azamian
President/CEO and Board Chair · sold 6,000 at $50.00
300K
0.7% of stake
Jun 17, 2025No plan
Jeffrey S Farrow
See Remarks · sold 13,608 at $40.42
550K
27% of stake
Jun 16, 2025No plan
Elizabeth Yeu Lin
Chief Medical Officer · sold 1,006 at $41.08
41K
2.7% of stake
Jun 9, 202510b5-1 plan
Aziz Mottiwala
Chief Commercial Officer · sold 17,500 at $43.76
766K
27% of stake
Mar 24, 202510b5-1 plan
Bobak R. Azamian
President/CEO and Board Chair · sold 6,000 at $50.00
300K
0.7% of stake
Mar 18, 2025 – Mar 20, 2025No plan
Aziz Mottiwala
Chief Commercial Officer · sold 10,565 at avg $47.88
506K
14% of stake
Mar 18, 2025 – Mar 20, 2025No plan
Seshadri Neervannan
Chief Operating Officer · sold 7,583 at avg $47.89
363K
8.7% of stake
Mar 18, 2025 – Mar 20, 2025No plan
Bryan Wahl
General Counsel · sold 9,686 at avg $47.88
464K
16% of stake
Mar 18, 2025 – Mar 20, 2025No plan
Dianne C. Whitfield
Chief Human Resources Officer · sold 6,711 at avg $47.88
321K
13% of stake
Mar 18, 2025 – Mar 20, 2025No plan
Bobak R. Azamian
President/CEO and Board Chair · sold 24,216 at avg $48.03
$1.16M
2.7% of stake
Mar 18, 2025 – Mar 20, 2025No plan
Jeffrey S Farrow
See Remarks · sold 3,724 at avg $47.88
178K
14% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch TARS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with TARS

CompareIntrinsic value

RGENRepligen Corporation

$178.20-0.04%35

ADMAAdma Biologics Inc.

$10.48-5.67%82

KRYSKrystal Biotech Inc.

$310.84+1.90%44

TWSTTwist Bioscience Corporation

$142.58+1.63%40

IMCRImmunocore Holdings plc

$29.23-2.66%40

BCRXBioCryst Pharmaceuticals Inc.

$8.24-3.85%64

NVAXNovavax Inc.

$10.65+10.02%10

MGTXMeiraGTx Holdings plc

$9.42-1.05%74

Held by ETFs

TARS is in 55 US ETFs. The largest of them, with TARS's weight in each:

Spot a number that looks wrong? Check it in TARS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing TARS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.